ShareCast - home
2 September 2010 
logo
spacer
Home
Home
News & Views
Top Stories
Finance Tools
Search
Name or ticker
About Us
Other Digital Look Sites
Register to get unlimited Level 2
CATEGORY: SMALL CAPS NEWS     SECTOR: CHEMICALS

Small caps round-up: Plantic Technologies, Acal, Anglesey

Thu 29 Jul 2010

PLNT - Plantic Technologies
chart
Latest Prices
Name Price %
Plantic Technologies 7.50p -1.67%
Acal 198.00p -2.94%
Anglesey Mining 26.25p +2.94%
Real Good Food Company 23.25p +19.23%
Synairgen 25.00p +2.00%
Serviced Office Group 2.88p -4.35%
 
FTSE AIM All-Share 702 +0.67%
FTSE Fledgling 4,098 +0.07%
Chemicals 5,653 +1.12%
Food Producers & Processors 4,665 -0.40%
Mining 21,219 -0.21%
Pharmaceuticals & Biotechnology 9,213 -0.03%
Real Estate Investment & Services 1,436 +1.65%
Support Services 3,856 +0.56%
Small caps round-up: Plantic Technologies, Acal, Anglesey LONDON (SHARECAST) - Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors.

Acal, which provides technology products and services across Europe and South Africa, said underlying sales for the first quarter increased by around 20% year on year and orders, a measure of current demand, increasing by 29%.

Anglesey Mining is up on news that its 41% owned associate company Labrador Iron Mines received approvals to commence construction of its mining facilities from the government of Newfoundland and Labrador.

Shares in bakery ingredients maker Real Good Food fell back after it reported good trading at its businesses, though the sugar business was impacted by lower prices.

Shares in office space provider Serviced Office climbed after it reported a widening in losses but said that recent changes including opening new buildings and developing a sales team should augur a return to profit.

In the half year to June 30, pre-tax losses widened to £272,000 from £207,000 over the same period the previous year, even as revenues jumped to £4.6m from £3.3m.

‘The changes we have made, coupled with the result to date, indicate a future return to profitability and I have great confidence in continued improvement going forwards,’ said chairman Michael Kingshott.

Respiratory drug discovery and development company Synairgen posted a pre-tax loss of £2.9m in the year to June 30, more than the £2.8m deficit the previous year as it continued its R&D programme.

print button
 
Visit Digital Look for more financial data and tools


 Front Page Stories

spacer back to topBack to top
The ShareCast news service is operated by Digital Look Ltd.
© Digital Look Ltd 1998-2010. All rights reserved. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please click here for our terms and conditions.